Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...

Plant immunity is largely initiated at the cellular level, with each cell capable of autonomous detection and response, while ...

One dog, one vaccine, one data point. The story of Rosie is fascinating – but it is not yet evidence that AI can beat cancer.

GeneDx Holdings Corp. (NASDAQ:WGS) is one of the most promising stocks under $100 to buy. On March 10, GeneDx and Zevra ...

Swiss pharma giant Novartis is to pay up to $3bn to Synnovation Therapeutics to acquire a promising breast-cancer treatment that has shown to reduce the unwanted side effects of available medicines.

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...

SNV4818 is an oral treatment being evaluated in an early and mid-stage study for breast cancer and other advanced solid ...

Genetic switches near the FTO locus may enable hibernators’ extreme metabolic resilience and could inspire future treatments ...

SNV4818 is an oral drug and is presently being assessed in an ongoing Phase I/II trial for breast cancer.

An Australian tech entrepreneur has helped create what appears to be a made-to-measure cancer vaccine for his dog, Rosie, using artificial ...

Stifel 2026 Virtual CNS Forum March 17, 2026 2:00 PM EDTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...